VPAC2 Antibody (5B3): sc-135604

VPAC2 Antibody (5B3) is a mouse monoclonal IgG2a kappa light chain antibody that detects VPAC2 protein of human origin by western blotting (WB), immunoprecipitation (IP), and enzyme-linked immunosorbent assay (ELISA). VPAC2 (5B3) antibody is available as a non-conjugated format. VPAC2 protein is a member of the vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) receptor family, which plays a crucial role in various physiological processes, including neuronal differentiation and immune response modulation. Located predominantly in the brain and T cells, VPAC2 interacts with both VIP and PACAP, activating adenylyl cyclase and subsequently increasing cyclic AMP levels, which is vital for signaling pathways that influence cell growth and function. VPAC2 receptor is part of a larger superfamily of G-protein coupled receptors, which also includes VPAC1 and PACAP receptor, each exhibiting unique expression patterns and signaling capabilities. VPAC2′s ability to mediate important cellular responses underscores its significance in neurobiology and immunology, making anti-VPAC2 antibody (5B3) an essential tool for researchers studying these pathways.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

VPAC2 Antibody (5B3) References:

1. Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions.  |  Vaudry, D., et al. 2000. Pharmacol Rev. 52: 269-324. PMID: 10835102
2. Overexpression of the human VPAC2 receptor in the suprachiasmatic nucleus alters the circadian phenotype of mice.  |  Shen, S., et al. 2000. Proc Natl Acad Sci U S A. 97: 11575-80. PMID: 11027354
3. Expression of vasoactive intestinal peptide (VIP) receptors in human uterus.  |  Bajo, AM., et al. 2000. Peptides. 21: 1383-8. PMID: 11072126
4. Vasoactive intestinal peptide: cardiovascular effects.  |  Henning, RJ. and Sawmiller, DR. 2001. Cardiovasc Res. 49: 27-37. PMID: 11121793
5. Selective gene expression and activation-dependent regulation of vasoactive intestinal peptide receptor type 1 and type 2 in human T cells.  |  Lara-Marquez, M., et al. 2001. J Immunol. 166: 2522-30. PMID: 11160313
6. Regulation of vasoactive intestinal peptide receptor expression in developing nervous systems.  |  Karacay, B., et al. 2000. Ann N Y Acad Sci. 921: 165-74. PMID: 11193820
7. Vasoactive intestinal peptide (VIP) receptor type 2 (VPAC2) is the predominant receptor expressed in human thymocytes.  |  Lara-Marquez, ML., et al. 2000. Ann N Y Acad Sci. 921: 45-54. PMID: 11193874
8. Pituitary adenylate cyclase-activating polypeptide (PACAP) and its receptors in the brain.  |  Shioda, S. 2000. Kaibogaku Zasshi. 75: 487-507. PMID: 11197592
9. c-Maf and JunB mediation of Th2 differentiation induced by the type 2 G protein-coupled receptor (VPAC2) for vasoactive intestinal peptide.  |  Voice, J., et al. 2004. J Immunol. 172: 7289-96. PMID: 15187104
10. Region-specific changes in the immunoreactivity of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide receptors (VPAC2, and PAC1 receptor) in the aged rat brains.  |  Lee, JC., et al. 2010. Brain Res. 1351: 32-40. PMID: 20599818
11. VIP Regulates Morphology and F-Actin Distribution of Schlemm's Canal in a Chronic Intraocular Pressure Hypertension Model via the VPAC2 Receptor.  |  Chen, L., et al. 2018. Invest Ophthalmol Vis Sci. 59: 2848-2860. PMID: 30025111
12. Cross-talk between fetal membranes and visceral adipose tissue involves HMGB1-RAGE and VIP-VPAC2 pathways in human gestational diabetes mellitus.  |  Santangelo, C., et al. 2019. Acta Diabetol. 56: 681-689. PMID: 30820673

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-VPAC2 Antibody (5B3) has 1 citations in a variety of scientific publications.

Primary antibodies like Anti-VPAC2 Antibody (5B3) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

VPAC2 Antibody (5B3) Specifications

Alternate Product Name: VPAC2

Product Clone Name: 5B3

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG_2a kappa light chain

Amino Acids: 24-127

Epitope Target: VPAC2

Epitope Species: human

Product Reactivity/Detection: VPAC2

Species Reactivity/Detection: human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, ELISA

Vialing Information: Each vial contains 100 µg IgG_2a kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 1 citations in various scientific publications

Available Conjugates/Forms for VPAC2 Antibody (5B3): N/A